Peripheral atherosclerosis and serum lipoprotein(a) in diabetes

Diabetes Care

Volumn 22, Issue 1, 1999, Pages 93-98

  Wollesen, Flemming ^a   Dahlén, Gösta ^b   Berglund, Lars ^a   Berne, Christian ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C PEPTIDE; HEMOGLOBIN A1C; HOMOCYSTEINE; LIPID; LIPOPROTEIN A; URIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY FAT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; TOE;

ARTERIOSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASES; PROBABILITY; REFERENCE VALUES; SWEDEN; TRIGLYCERIDES;

EID: 0032907284     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.1.93     Document Type: Article

References (62)

1. Scanu AM: Genetic basis and pathophysiological implications of high plasma Lp (a) levels. J Intern Med 231:679-683, 1992
2. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM: Association of levels of lipoprotein Lp (a), plasma lipicls, and other lipoproteins with coronary artery disease documented by angiography Circulation 74:758-765, 1986
3. Willeit J, Kiechl S, Santer P, Oberhollenzer F, Egger G, Jarosch E, Mair A: Lipoprotein (a) and asymptomatic carotid artery disease: evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke 26:1582-1587, 1995
4. Sutton-Tynell K, Evans RW, Meilahn E, Alcorn HG: Lipoprotein (a) and peripheral atherosclerosis in older adults. Atherosclerosis 122:11-19, 1996
5. Rhoads GG, Dahlen G, Berg K, Morton N, Dannerberg AL: Lp (a) lipoprotein as a risk factor for myocardial infarction. JAMA 256:2540-2544, 1986
6. Schaefer EJ, Lamon Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI: Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999-1003, 1994
7. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, Wieland H: Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome. Ann Intern Med 119:263-269, 1993
8. Jenkins AJ, Steele JS, Janus ED, Santamaria JD, Best JD: Plasma apolipoproiein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 35:1055-1059, 1992
9. Cummings MH, Watts GF, Tavakolian A, Fitzgerald A: Prevalence of microalbuminuria, lipoprotein (a) and coronary artery disease in the lipid clinic. J Clin Pathol 49:19-23, 1996
10. Haffner SM, Tuttle KR, Rainwater DL: Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabeto Care 14:302-307, 1991
11. Ritter MM, Richter WO, Lyko K, Schwandt P: Lp(a) serum concentrations and metabolic control. Diabetes Care 15:1441-1442, 1992
12. Maser RE, Usher D, Becker DJ, Drash AL, Kuller LH, Orchard TJ: Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh Epidemiology of Diabetes Complications Study cohort. Diabetes Care 16:755-758, 1993
13. Klausen IC, Schmidt EB, Lervang HH, Gerdes LU, Ditzel J, Faergeman O: Normal lipoprotein (a) concentrations and apolipoprotein (a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 22:538-541, 1992
14. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD: Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218-1226, 1995
15. Imperatore G, Rivellese A, Galasso R, Celentano E, Lovine C, Ferrara A, Riccardi G, Vaccaro O: Lipoprotein (a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: a population-based study. Metabolism 44:1293-1297, 1995
16. Heller FR, Jamart J, Honore P, Derue G, Novik V, Galanti L, Parfonry A, Hondekijn JC, Buysschaert M: Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care 16:819-823, 1993
17. Velho G, Erlich D, Turpin E, Neel D, Cohen D, Froguel P, Passa P: Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care 16:742-747, 1993
18. Csaszar A, Dieplinger H, Sandholzer C, Karadi I, Juhasz E, Drexel H, Romics L, Patsch JR, Utermann G: Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus. Diabetologia 36:47-51, 1993
19. Haffner SM, Morales PA, Stern MP, Gruber MK: Lp(a) concentrations in NIDDM. Diabetes 41:1267-1272, 1992
20. Rainwater DL, MacCluer JW, Stern MP, VandeBerg JL, Haffner SM: Effect of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes 43:942-946, 1994
21. Joven J, Vilella E: Serum levels of lipoprotein (a) in patients with well-controlled non-insulin-dependent diabetes mellitus. JAMA 265:1113-1114, 1991
22. Watts GF, ap Gwilym RM, Mazurkiewicz J, Coltart J: Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM. Diabetes Care 18:234-236, 1995
23. Yamamoto M, Egusa G, Yamakido M: Carotid atherosclerosis and serum lipoprotein(a) concentrations in patients with NIDDM. Diabetes Care 20:829-831, 1997
24. James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D: Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 38:711-714, 1995
25. Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, Froguel P, Passa P: Association of elevated lipoprotein (a) levels and coronary heart disease in NIDDM patients: relationship with apolipoprotein (a) phenotypes. Diabetologia 37:585-591, 1994
26. Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, Murase T: Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 18:241-244, 1995
27. Ritter MM, Loscar M, Richter WO, Schwandt P: Lipoprotein (a) in diabetes mellitus. Clin Chim Acta 214:45-54, 1993
28. Haffner SM, Moss SE, Klein BE, Klein R: Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiological Study of Diabetes Retinopathy. Metabolism 41:194-197, 1992
29. Winocour PH, Durrington PN, Bhatnagar D, MBewu AD, Ishola M, Mackness M, Arrol S: A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract 18:173-184, 1992
30. Levitsky LL, Scanu AM, Gould SH: Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care 14:283-287, 1991
31. Bruckert E, Davidoff P, Grimaldi A, Truffert J, Giral P, Doumith R, Thervet F, De Gennes JL: Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control (Letter). JAMA 263:35-36, 1990
32. O'Brien T, Nguyen TT, Harrison JM, Bailey KR, Dyck PJ, Kottke BA: Lipids and Lp (a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 69:430-435, 1994
33. Haffner SM, Tuttle KR, Rainwater DL: Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes. Metabolism 41:116-120, 1992
34. Nakata H, Horita K, Eto M: Alteration of lipoprotein (a) concentration with glycemic control in non-insulin-dependent diabetic subjects without diabetic complications. Metabolism 42:1323-1326, 1993
35. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P: Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 117:42-47, 1992
36. Wolffenbuttel BH, Leurs PB, Sels JP, Rondas Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC: Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein (a) levels Diabet Med 10:427-430, 1993
37. Heesen BJ, Wolffenbuttel BH, Leurs PB, Sels JP, Menheere PP, Nieuwenhuijzen Kruseman AC: Lipoprotein (a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest 23:580-584, 1993
38. Guillausseau PJ, Peynet J, Chanson P, Legrand A, Altman JJ, Poupon J, N'Guyen M, Rousselet F, Lubetzki J: Lipoprotein(a) in diabetic patients with and without chronic renal failure. Diabetes Care 15:976-979, 1992
39. Dahlen GH, Slunga L, Holmlund G, Lango A, Lindblom B: Lp (a) lipoprotein and HLA-DR genotype in early coronary artery disease. Eur J Immunogen 20:95-102, 1993
40. Heding LG: Radioimmunological determinations of human C-peptide in serum. Diabetologia 11:541-548, 1975
41. Newman AB, Siscovick DS, Manolio TA: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study: Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 88:837-845, 1993
42. Orchard TJ, Strandness DE Jr: Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association, September 18-20, 1992, New Orleans, Louisiana [AHA medical/scientific statement]. Circulation 88:819-828, 1993
43. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116-1124, 1990
44. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ: Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20:384-392, 1991
45. Carter SA, Lezack JD: Digital systolic pressures in the lower limb in arterial disease. Circulation 43:905-914, 1971
46. Criqui MH, Fronek A, Barrett Connor E, Klauber MR, Gabriel S, Goodman D: The prevalence of peripheral arterial disease in a defined population. Circulation 71:510-515, 1985
47. 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest 41:611-616, 1981
48. Anderson KM, Odell PM, Wilson PWF, Kannel WB: Cardiovascular disease risk profiles. Am Heart J 121:293-298, 1991
49. Frane J: All possible subsets regression. In BMDP Statistical Software Manual. Vol. 4. Dixon WJ, Brown MB, Engelman L, Jennrich RI, Eds. Berkeley, University of California Press, 1990, p. 993-1012
50. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151:1141-1147, 1991
51. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM: Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 96:1639-1646, 1995
52. Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS, Dobs A, Evans GW, Heiss G: Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 131:115-125, 1997
53. Kornitzer M, Dramaix M, Sobolski J, Degre S, De Backer G: Ankle/arm pressure index in asymptomatic middle-aged males: an independent predictor of ten-year coronary heart disease mortality Angiology 46:211-219, 1995
54. Dahlen GH: Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis 108:111-126, 1994
55. Schreiner PJ, HeissG, Tyroler HA, Morrisett JD, Davis CE, Smith R: Race and gender differences in the association of Lp (a) with carotid artery wall thickness: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 16:471-478, 1996
56. Anonymous: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894-903, 1995
57. Takegoshi T, Haba T, Hirai J, Kitoh C, Saga T, Yamazaki Y, Mabuchi H: Alterations of lipoprotein (a) in patients with diabetic nephropathy. Atherosclerosis 83:99-100, 1990
58. Jenkins AJ, Steele JS, Janus ED, Best JD: Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 40:787-790, 1991
59. Irish AB, Simons LA, Simons J: Lipoprotein (a) concentration in diabetes: relationship to proteinuria and diabetes control. Aust N Z J Med 22:329-333, 1992
60. Groop PH, Viberti GC, Elliott TG, Friedman R, Mackie A, Ehnholm C, Taskinen MR: Lipoprotein (a) in type 1 diabetic patients with renal disease. Diabet Med 11:961-967, 1994
61. Guerci B, Igau B, Ziegler O, Crea T, Fruchart JC, Drouin P, Fievet C: Lack of relationship between Lp (a) particle levels and albumin excretion rate in type 1 diabetic patients. Diabete Metab 20:526-531, 1994
62. Haffner SM, Morales PA, Gruber MK, Hazuda HP, Stern MP: Cardiovascular risk factors in non-insulin-dependent diabetic subjects with microalbuminuna. Arterioscler Thromb 13:205-210, 1993